Dual targeting strategies with bispecific antibodies
Top Cited Papers
Open Access
- 1 March 2012
- journal article
- review article
- Published by Informa UK Limited in mAbs
- Vol. 4 (2), 182-197
- https://doi.org/10.4161/mabs.4.2.19000
Abstract
Monoclonal antibodies are widely used for the treatment of cancer, inflammatory and infectious diseases and other disorders. Most of the marketed antibodies are monospecific and therefore capable of interacting and interfering with a single target. However, complex diseases are often multifactorial in nature, and involve redundant or synergistic action of disease mediators or upregulation of different receptors, including crosstalk between their signaling networks. Consequently, blockade of multiple, different pathological factors and pathways may result in improved therapeutic efficacy. This result can be achieved by combining different drugs, or use of the dual targeting strategies applying bispecific antibodies that have emerged as an alternative to combination therapy. This review discusses the various dual targeting strategies for which bispecific antibodies have been developed and provides an overview of the established bispecific antibody formats.Keywords
This publication has 149 references indexed in Scilit:
- Heavy chain-only antibodies and tetravalent bispecific antibody neutralizing Staphylococcus aureus leukotoxinsProceedings of the National Academy of Sciences of the United States of America, 2011
- Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodiesProceedings of the National Academy of Sciences of the United States of America, 2011
- Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopesProceedings of the National Academy of Sciences of the United States of America, 2011
- The Bs20x22 anti-CD20-CD22 bispecific antibody has more lymphomacidal activity than do the parent antibodies aloneCancer Immunology, Immunotherapy, 2011
- Chemical generation of bispecific antibodiesProceedings of the National Academy of Sciences of the United States of America, 2010
- A novel bispecific ligand-directed toxin designed to simultaneously target EGFR on human glioblastoma cells and uPAR on tumor neovasculatureJournal of Neuro-Oncology, 2010
- Monoclonal antibody-based therapies for microbial diseasesVaccine, 2009
- Genetic alteration of a bispecific ligand-directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancyLeukemia Research, 2009
- Design and modification of EGF4KDEL 7Mut, a novel bispecific ligand-directed toxin, with decreased immunogenicity and potent anti-mesothelioma activityBritish Journal of Cancer, 2009
- The epidermal growth factor receptor family: Biology driving targeted therapeuticsCellular and Molecular Life Sciences, 2008